Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Androgen-Resistant Prostatic Neoplasms”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06844383
What this trial is testing

Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide

Who this might be right for
Prostate Cancer (Adenocarcinoma)mCRPC (Metastatic Castration-resistant Prostate Cancer)
Prostate Cancer Clinical Trials Consortium 126
Testing effectiveness (Phase 2)Ended earlyNCT03437941
What this trial is testing

Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer
Corcept Therapeutics 39
Testing effectiveness (Phase 2)Study completedNCT02814968
What this trial is testing

PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide

Who this might be right for
Prostate Cancer Metastatic
The European Uro-Oncology Group 66
Not applicableLooking for participantsNCT07538843
What this trial is testing

An Observational Study Conducted in China to Evaluate the Efficacy and Safety of Darolutamide in Combination With Androgen Deprivation Therapy (ADT) for Men With Non-metastatic Prostate Cancer That Progressed Following Prior Bicalutamide + ADT Treatment

Who this might be right for
Non-metastatic Castration-resistant Prostate Cancer
Bayer 800
Large-scale testing (Phase 3)Looking for participantsNCT06855277
What this trial is testing

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

Who this might be right for
Prostate Cancer
Novartis Pharmaceuticals 940
Testing effectiveness (Phase 2)Study completedNCT00544440
What this trial is testing

An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma

Who this might be right for
Prostate Neoplasms
Janssen Research & Development, LLC 57
Early research (Phase 1)Temporarily pausedNCT01337518
What this trial is testing

A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer

Who this might be right for
Prostatic Neoplasm
Enzon Pharmaceuticals, Inc. 150
Not applicableEnded earlyNCT00743327
What this trial is testing

Androgen Deprivation Therapy Study

Who this might be right for
HypogonadismMetabolic SyndromeDiabetes+1 more
National Institute on Aging (NIA) 1
Testing effectiveness (Phase 2)Study completedNCT04335682
What this trial is testing

Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide

Who this might be right for
Metastatic Prostate CancerProstate Cancer MetastaticProstate Cancer+3 more
Alliance Foundation Trials, LLC. 111
Early research (Phase 1)Ended earlyNCT05295927
What this trial is testing

EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostatic Neoplasms
Janssen Research & Development, LLC 3
Testing effectiveness (Phase 2)Ended earlyNCT04737109
What this trial is testing

Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer

Who this might be right for
Castrate Resistant Prostate Cancer
David VanderWeele 6
Not applicableLooking for participantsNCT06141993
What this trial is testing

ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials

Who this might be right for
Prostate CancerProstate AdenocarcinomaProstate Cancer Metastatic+1 more
Duke University 120
Testing effectiveness (Phase 2)Study completedNCT03554317
What this trial is testing

COMbination of Bipolar Androgen Therapy and Nivolumab

Who this might be right for
Castration-resistant Prostate CancerMetastatic Prostate CancerProstate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 45
Testing effectiveness (Phase 2)Ended earlyNCT00918385
What this trial is testing

Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Duke University 57
Testing effectiveness (Phase 2)Study completedNCT01254864
What this trial is testing

Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies

Who this might be right for
Prostate Cancer
M.D. Anderson Cancer Center 190
Early research (Phase 1)Ended earlyNCT03478904
What this trial is testing

Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer

Who this might be right for
Prostate Cancer
National Cancer Institute (NCI) 1
Testing effectiveness (Phase 2)Ended earlyNCT01545882
What this trial is testing

A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate Cancer

Who this might be right for
Prostatic Neoplasms
Ottawa Hospital Research Institute 5
Testing effectiveness (Phase 2)Study completedNCT02346578
What this trial is testing

Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.

Who this might be right for
Castration-resistant Prostate Cancer
Taro Iguchi, MD, PHD 104
Not applicableActive Not RecruitingNCT07126860
What this trial is testing

The Effect of a Structured Strength and Endurance Training Program on Quality of Life, Fitness, Blood Parameters and Survival in Prostate Cancer Patients

Who this might be right for
Prostate CancerMetastatic Prostate CancerProstate Cancer (Post Prostatectomy)+2 more
Ludwig-Maximilians - University of Munich 150
Testing effectiveness (Phase 2)Active Not RecruitingNCT05658003
What this trial is testing

A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 63
Next Page